Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451828 · ClinicalTrials.gov registry record · Phase 4
Cholesterol and Pharmacogenetic Study
A Phase 4 study of Cardiovascular Disease and Hypercholesterolemia, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT00451828 is a Phase 4 study of Cardiovascular Disease and Hypercholesterolemia that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 1,000 participants, below the 2,706-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00451828, a Phase 4 study of Cardiovascular Disease and Hypercholesterolemia, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of the CAP study was to determine genetic influences on efficacy of simvastatin treatment with regard to LDL cholesterol reduction and changes in other markers of cardiovascular disease risk.
Conditions Studied
Interventions
- DRUG Simvastatin
Study Locations (1)
California
- San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2002-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00451828
The ClinicalTrials.gov registry entry for NCT00451828 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,706-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (63% lower). The listed sponsor is UCSF Benioff Children's Hospital Oakland, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Simvastatin is the first listed.
NCT00451828 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00451828 about?
NCT00451828 is a clinical study titled "Cholesterol and Pharmacogenetic Study". The overall objective of the CAP study was to determine genetic influences on efficacy of simvastatin treatment with regard to LDL cholesterol reduction and changes in other markers of cardiovascular disease risk.
What is the current status of trial NCT00451828?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,000 participants. The study started on 2002-03.
What conditions does trial NCT00451828 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Hypercholesterolemia, Hyperlipidemia, Coronary Heart Disease.
What interventions are being tested in trial NCT00451828?
The interventions under investigation include: Simvastatin (DRUG).
Who is sponsoring clinical trial NCT00451828?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00451828 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beta-Blocker Influences on Inflammatory and Neural Responses to Stress
RECRUITING · Phase 4
-
Randomized Trial of SGLT2i in Heart Transplant Recipients
RECRUITING · Phase 4
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
MIcrovascular dysfuNction In Moderate-severe Psoriasis
COMPLETED · Phase 4
-
Phosphate Lowering in CKD Trial
COMPLETED · Phase 4
-
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.